Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070167 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL9067361 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385198 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385408 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29386171 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5173973 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385929 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL10791516 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL7746290 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5173963 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 953 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029185-A | TNF receptor 2 specific agonist fusion proteins comprising a TNF homology domain and a mutated Fc domain | 雷萨诺有限责任公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-12552867-B2 | Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains | LEADARTIS, S.L. (ES) | 2026-02-17 | — | — | US | claimed |
| US-20260035435-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | Astero BioPharma LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-20250382348-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | Astero BioPharma LLC (US) | 2025-12-18 | — | — | US | claimed |
| US-20250381256-A1 | SUBLINGUAL NANOFIBER VACCINES AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2025-12-18 | — | — | US | claimed |
| US-20250281629-A1 | COMPOSITIONS AND METHODS FOR ANTI-PHOSPHOCHOLINE ACTIVE IMMUNOTHERAPY | DUKE UNIVERSITY | 2025-09-11 | — | — | US | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| CN-115768801-A | Engineered relaxin and methods of use thereof | 哈佛学院院长等 | 2023-03-07 | — | — | CN | claimed |
| WO-2023000240-A1 | LONG-ACTING GLP-1 POLYPEPTIDE ANALOGUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛博睿精创科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| EP-4078180-A1 | A LIBRARY OF PREFABRICATED MICROPARTICLES AND PRECURSORS THEREOF | Blink AG (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-115176156-A | Library of preformed microparticles and precursors thereof | 布林克公司 | 2022-10-11 | — | — | CN | claimed |
| US-20220281985-A1 | SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS | LEADARTIS S L (ES) | 2022-09-08 | — | — | US | claimed |
| WO-2022178367-A2 | SINGLE-CHAIN AND MULTI-CHAIN SYNTHETIC ANTIGEN RECEPTORS FOR DIVERSE IMMUNE CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022140373-A1 | THERAPEUTIC PEPTIDE FORMULATIONS | ELI LILLY AND COMPANY (US) | 2022-06-30 | — | — | WO | claimed |
| CN-114539358-A | Polypeptide, preparation method and application | 中国科学院大连化学物理研究所 | 2022-05-27 | — | — | CN | claimed |
| US-11306147-B2 | Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains | LEADARTIS, S.L. (ES) | 2022-04-19 | — | — | US | claimed |
| WO-2022060904-A1 | COMPOSITIONS AND METHODS FOR EXPRESSION OF T-CELL RECEPTORS WITH SMALL MOLECULE-REGULATED CD40L IN T CELLS | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281629-A1 | COMPOSITIONS AND METHODS FOR ANTI-PHOSPHOCHOLINE ACTIVE IMMUNOTHERAPY | PHOSPHO1, CD47, PLA2G2C | ALDH1A1 3944/4885MAPT 122/4885LMNA 1265/4885 |
| US-20260035435-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | PLA2G2D, FCGR2A, PLA2R1 | ALDH1A1 4782/4885MAPT 4559/4885LMNA 4012/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | ALDH1A1 3744/4885MAPT 1052/4885LMNA 3936/4885 |
| US-12552867-B2 | Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains | COL1A1, COL2A1, COL14A1 | ALDH1A1 4579/4885MAPT 1783/4885LMNA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.